| --- | --- | --- | |-----------------------|-------|--------------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Q2'23 Earnings Report | | | | August 3, 2023 | | Nasdaq: COLL | Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipat ...

Table of Contents As of June 30, 2023, none of the above circumstances had occurred and as such, the 2026 Convertible Notes could not have been converted. (1) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (2) the trading day immediately before the date the Company sends such notice. The 2026 Convertible Notes have customary default ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Christopher James - Vice President, Investor Relations Joe Ciaffoni - Chief Executive Officer Colleen Tupper - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler Tim Lugo - William Blair Brandon Folkes - Cantor Fitzgerald Serge Belanger - Needham & Company Greg Fraser - Truist Securities Glen Santangelo - Jefferies ...

On February 25, 2022, in connection with the BDSI Acquisition, a purported individual stockholder of BDSI filed a complaint in the United States District Court for the Southern District of New York, captioned Stein v. BioDelivery Sciences International, Inc., et al., No. 1:22-cv-01600, naming as defendants BDSI and each member of its Board of Directors as of the date of the Merger Agreement ("Stein Action"). On February 28, 2022, two additional cases were filed by purported individual stockholders of BDSI i ...

Forward-Looking Statements To supplement our financial results presented on a GAAP basis, we have included information about certain non-GAAP financial measures. We use these non-GAAP financial measures to understand, manage and evaluate our business as we believe they provide additional information on the performance of our business. We believe that the presentation of these non-GAAP financial measures, taken in conjunction with our results under GAAP, provide analysts, investors, lenders and other third p ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Christopher James - Vice President of Investor Relations at Collegium Pharmaceuticals Joe Ciaffoni - Chief Executive Officer Colleen Tupper - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler Brandon Folkes - Cantor Fitzgerald Serge Belanger - Needham & Company Greg Fraser - Truist Operator Greetings, and we ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Securities registered pursuant to Section 12(g) of the Act: None Commission File Number 001-37372 Collegium Pharmaceutical, Inc. (Exact name of registrant as specified in its cha ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Dawn Schottlandt - Managing Director-Argot Partners Joe Ciaffoni - Chief Executive Officer Colleen Tupper - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler Tim Lugo - William Blair Brandon Folkes - Cantor Fitzgerald Serge Belanger - Needham & Company Greg Fraser - Truist Securities Oren Livnat - H.C. Wainwri ...

November 3, 2022 | Nasdaq: COLL Q3FY22 Earnings Report | --- | --- | |----------------------------|-------| | | | | Forward-Looking Statements | | Non-GAAP Financial Measures | --- | --- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37372 Collegium Pharmaceutical, Inc. (Exact name of registrant as specified in its charter) Virginia (Sta ...